Pharmaceutical Technology Editors

Forest's planned acquisition of Aptalis will enhance its business in gastrointestinal and cystic fibrosis therapies.

Eurofins acquires DDS business of Merck KGaA in order to expand discovery solutions and bioanalytical services.

FDA releases guidance on developing drugs for the treatment of community-acquired bacterial pneumonia.

Ron Piervincenzi to assume leadership of the United States Pharmacopeial Convention on Feb. 1, 2014.

EMA has launched a new version of the EudraGMDP database, which includes the publication of statements of non-compliance with good manufacturing practice.

GE acquires Thermo Fisher's HyClone cell culture media and sera products, gene modulation technologies, and magnetic beads businesses.

A study led by Stanford University explains why men may have weaker responses to vaccines than women.

A monkey-vaccine study provides insight into HIV research.

Roche?s Brain Shuttle technology transfers antibodies through the BBB.

Mac Process will merge with Schenck AccuRate and combine their operations under the name of Schenck Process.

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Abrams Royal Pharmacy is recalling all unexpired lots of sterile products dispensed in the US.

Baxter International recalls dextrose injection and four sodium chloride injections.

This month, healthcare leaders from six of the world's top 20 pharmaceutical companies met together in collaboration with the Oliver Wyman Health Innovation Center to explore the industry's changing role in today's value-basaed healthcare structure.

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI's LifeSciences business unit for $185 million.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

A collaborative pharmaceutical project to develop paediatric formulations using smart design and predictive science has received the go ahead after securing a ?660,000 grant from UK-based Technology Strategy Board.

FDA completes an inspection of Cambrex's API manufacturing facility in Charles City, Iowa.

Metrics appoints a new vice-president to manage and expand its fee-for-service operations.

CMC Biologics and OnoSynergy form an agreement from cell-line development.

Pfizer appoints management changes to take effect in 2014.

Merck Serono, the biopharmaceutical division of Merck, has entered into an agreement on cancer drug development with the Spanish National Cancer Research Centre (CNIO) in Madrid.

FDA and EMA launch initiative to share bioequivalence inspection information.

Bridgepoint Development Capital acquires Quotient for an undisclosed sum.

Accelrys aquires Ireland-based Qumas, a provider of cloud-based and on-premises enterprise compliance software.

Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.

AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.

Roche announces changes to its board of directors scheduled for March 4, 2014.

FDA has issued a proposed rule to require manufacturers of antibacterial hand soaps and body washes to demonstrate that their products are safe for long-term daily use and more effective than plain soap and water.